Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and γ-IFN levels in serum and cerebrospinal fluid

https://doi.org/10.1016/0022-510X(89)90171-8Get rights and content

Abstract

Serum and cerebrospinal fluid (CSF) levels of interleukin-2 (IL-2), soluble IL-2 receptor (sIL-2R), and gamma-interferon (γ-IFN) were measured in multiple sclerosis (MS) patients, human immunodeficiency virus type 1 (HIV-1)-infected patients and normal controls (NC). Increased levels of both IL-2 and sIL-2R were found in MS serum. Moreover, 11 of 50 MS patients showed detectable levels of IL-2 in the CSF. HIV-1-infected patients had increased levels of sIL-2R in serum and, less frequently, in the CSF. γ-IFN was never detected in serum and CSF of all the patients studied. These findings confirm preliminary reports, further stress a systemic T-cell activation in MS, and support the hypothesis that an immunologic disorder exists in such patients.

References (36)

  • A. Billiau et al.

    A role for the interferon system in Multiple Sclerosis

  • E. Braakman et al.

    Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit

    Clin. Exp. Immunol.

    (1986)
  • P. Gallo et al.

    Detection of IgG oligoclonal bands in unconcentrated CSF by means of agarose isoelectric focusing, double immunofixation, peroxidase staining, and avidin-biotin amplification

    Ital. J. Neurol. Sci.

    (1985)
  • P. Gallo et al.

    Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients

    Ann. Neurol.

    (1988)
  • P. Gallo et al.

    Central nervous system involvement in HIV infection

    AIDS Res. Hum. Retroviruses

    (1988)
  • J. Golaz et al.

    Activated T-lymphocytes in patients with multiple sclerosis

    Neurology (NY)

    (1983)
  • S.L. Greenberg et al.

    Elevated levels of soluble interleukin-2 receptors in multiple sclerosis

    N. Engl. J. Med.

    (1988)
  • D.A. Hafler et al.

    In vivo activated T-cells in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

    N. Engl. J. Med.

    (1985)
  • Cited by (88)

    • Type 2 Innate Lymphoid Cells Induce CNS Demyelination in an HSV-IL-2 Mouse Model of Multiple Sclerosis

      2020, iScience
      Citation Excerpt :

      Several lines of evidence suggest that the cytokine IL-2 is involved in demyelination during MS progression. First, the number of IL-2-secreting cells and amount of IL-2 in the sera of MS patients are elevated (Gallo et al., 1988, 1989; Lu et al., 1993; Trotter et al., 1989), and second, levels of soluble IL-2 receptor (sIL-2r) are increased in both the sera (Bansil et al., 1991; Gallo et al., 1989; Greenberg et al., 1988; Hartung et al., 1990; Traugott, 1987) and CSF of MS patients (Adachi et al., 1989; Kittur et al., 1990). In addition, supernatants from MS patients' T lymphocytes cause damage to myelin and glial cells in vitro (Selmaj et al., 1988a, b), suggesting that MS T lymphocytes are pre-activated in vivo to produce demyelination factors.

    • KIR2DL4-HLAG interaction at human NK cell-oligodendrocyte interfaces regulates IFN-γ-mediated effects

      2019, Molecular Immunology
      Citation Excerpt :

      IFN-α and IL-2 enhance ex vivo natural killer (eNK) cell cytotoxicity against the prototypical erythroleukemic target cell line, K562 (Trinchieri et al., 1984). IL-2, which is elevated in MS patient serum (Gallo et al., 1989), additionally enhances NK cell cytotoxicity against human oligodendrocytes isolated from human brain (Morse et al., 2001). IFN-α-induced cytotoxicity of NK cells is governed by certain activating receptors such as NKG2D and CD161 (Konjevic et al., 2010), and the role of different types of IFNs in MS has been described (Reder and Feng, 2014; Dumitrescu et al., 2018).

    • An ex-vivo multiple sclerosis model of inflammatory demyelination using hyperbranched polymer

      2013, Biomaterials
      Citation Excerpt :

      Reported levels of IFNγ in MS patients have shown conflicting results. Some studies reported elevated IFNγ levels (4–256 U/ml) in serum of MS patients [45], while other studies have reported no change compared to controls [46]. Our studies showed a transient threefold increase in released IFNγ two days after transfection compared with controls.

    View all citing articles on Scopus
    View full text